NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.38
  • Forecasted Upside: 297.06 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$0.85
▼ -0.03 (-3.41%)
1 month | 3 months | 12 months
Get New Matinas BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTNB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTNB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$3.38
▲ +297.06% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Matinas BioPharma in the last 3 months. The average price target is $3.38, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a 297.06% upside from the last price of $0.85.
Buy
The current consensus among 4 investment analysts is to buy stock in Matinas BioPharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
3/30/2021HC WainwrightReiterated RatingBuy$4.00 ➝ $3.00
i
2/15/2021AegisReiterated RatingBuy
i
Rating by N. Weinstein at Aegis
1/29/2021Maxim GroupReiterated RatingBuy$3.00
i
1/4/2021Piper SandlerBoost Price TargetOverweight$1.80 ➝ $4.00
i
11/6/2020Maxim GroupInitiated CoverageBuy$3.00
i
Rating by Jason McCarthy at Maxim Group
8/13/2020AegisBoost Price TargetBuy$3.25 ➝ $3.50
i
Rating by N. Weinstein at Aegis
8/11/2020HC WainwrightReiterated RatingBuy$4.00
i
6/2/2020AegisReiterated RatingBuy
i
Rating by N. Weinstein at Aegis
5/23/2020Maxim GroupInitiated CoverageBuy$3.00
i
Rating by Jason McCarthy at Maxim Group
5/13/2020Maxim GroupReiterated RatingBuy
i
Rating by Jason McCarthy at Maxim Group
4/1/2020Maxim GroupInitiated CoverageBuy$3.00
i
Rating by Jason McCarthy at Maxim Group
3/6/2020Maxim GroupReiterated RatingBuy
i
1/26/2020Piper SandlerInitiated CoverageOverweight$3.00
i
Rating by Edward Tenthoff at Piper Sandler
1/23/2020SunTrust BanksInitiated CoverageBuy$3.00
i
1/9/2020AegisInitiated CoverageBuy$3.50
i
12/20/2019HC WainwrightReiterated RatingBuy$4.00
i
Rating by A. Fein at HC Wainwright
9/26/2019Maxim GroupReiterated RatingBuy$3.00
i
8/14/2019HC WainwrightReiterated RatingBuy$4.00
i
Rating by A. Fein at HC Wainwright
6/26/2019HC WainwrightReiterated RatingBuy
i
Rating by A. Fein at HC Wainwright
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$4.00
i
Rating by A. Fein at HC Wainwright
5/17/2019BTIG ResearchInitiated CoverageBuy$5.00
i
5/16/2019Maxim GroupReiterated RatingBuy$5.00
i
2/11/2019Roth CapitalReiterated RatingBuy
i
Rating by J. Isaacson at Roth Capital
2/11/2019Roth CapitalInitiated CoverageBuy$4.75
i
Rating by J. Isaacson at Roth Capital
11/12/2018Maxim GroupBoost Price TargetBuy ➝ Buy$2.00 ➝ $5.00
i
8/13/2018Maxim GroupLower Price TargetBuy ➝ Buy$3.00 ➝ $2.00
i
Rating by Jason McCarthy at Maxim Group
7/10/2018Maxim GroupLower Price TargetBuy ➝ Buy$4.00 ➝ $3.00
i
Rating by Jason McCarthy at Maxim Group
5/10/2018Maxim GroupSet Price TargetBuy$4.00
i
Rating by Jason McCarthy at Maxim Group
4/23/2018Maxim GroupSet Price TargetBuy$4.00
i
Rating by Jason McCarthy at Maxim Group
3/19/2018Maxim GroupSet Price TargetBuy$6.00
i
Rating by Jason McCarthy at Maxim Group
8/10/2017Roth CapitalSet Price TargetBuy$9.00
i
Rating by Michael Higgins at Roth Capital
8/8/2017Maxim GroupSet Price TargetBuy$6.00
i
Rating by Jason McCarthy at Maxim Group
7/10/2017Roth CapitalReiterated RatingBuy
i
Rating by M. Higgins at Roth Capital
7/10/2017Roth CapitalInitiated CoverageBuy$9.00
i
6/26/2017Maxim GroupReiterated RatingBuy$6.00
i
Rating by Jason McCarthy at Maxim Group
6/5/2017Maxim GroupSet Price TargetBuy$6.00
i
Rating by Jason McCarthy at Maxim Group
5/16/2017Maxim GroupSet Price TargetBuy$6.00
i
Rating by Jason McCarthy at Maxim Group
4/3/2017Maxim GroupReiterated RatingBuy$6.00
i
Rating by Jason McCarthy at Maxim Group
3/28/2017AegisReiterated RatingBuy ➝ Positive$8.00
i
3/27/2017Maxim GroupReiterated RatingBuy$6.00
i
Rating by Jason McCarthy at Maxim Group
3/2/2017Maxim GroupSet Price TargetBuy$6.00
i
Rating by Jason McCarthy at Maxim Group
11/21/2016Maxim GroupInitiated CoverageBuy
i
11/1/2016AegisInitiated CoverageBuy
i
(Data available from 4/21/2016 forward)
Matinas BioPharma logo
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.
Read More

Today's Range

Now: $0.85
$0.82
$0.89

50 Day Range

MA: $1.11
$0.88
$1.74

52 Week Range

Now: $0.85
$0.64
$2.22

Volume

1,476,001 shs

Average Volume

4,509,777 shs

Market Capitalization

$173.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3

Frequently Asked Questions

What sell-side analysts currently cover shares of Matinas BioPharma?

The following Wall Street analysts have issued stock ratings on Matinas BioPharma in the last year: Aegis, HC Wainwright, Maxim Group, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for MTNB.

What is the current price target for Matinas BioPharma?

4 Wall Street analysts have set twelve-month price targets for Matinas BioPharma in the last year. Their average twelve-month price target is $3.38, suggesting a possible upside of 297.1%. Piper Sandler has the highest price target set, predicting MTNB will reach $4.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Matinas BioPharma in the next year.
View the latest price targets for MTNB.

What is the current consensus analyst rating for Matinas BioPharma?

Matinas BioPharma currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MTNB will outperform the market and that investors should add to their positions of Matinas BioPharma.
View the latest ratings for MTNB.

What other companies compete with Matinas BioPharma?

How do I contact Matinas BioPharma's investor relations team?

Matinas BioPharma's physical mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company's listed phone number is +1-908-4431860 and its investor relations email address is [email protected] The official website for Matinas BioPharma is www.matinasbiopharma.com.